Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2276 April 2025

APPLICANT (stamp or sticker acceptable)		PATIENT NHI:	REFERRER Reg No:	
Reg No:		First Names:	First Names:	
Name:		Surname:	Surname:	
Address:		DOB:	Address:	
		Address:		
Fax Number:			Fax Number:	
Pertuzumab				
Initial application — metastatic breast cancer Applications from any relevant practitioner. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)  The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)  Patient is chemotherapy treatment naïve  or  Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer  and  The patient has good performance status (ECOG grade 0-1) and  Pertuzumab to be administered in combination with trastuzumab and  Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks  Pertuzumab to be discontinued at disease progression				
Renewal — metastatic breast cancer  Current approval Number (if known):				
and	·	reast cancer expressing HER-2 IHC 3+ or ISH+ (inclused at any time point during the previous 12 months v		
orand	Patient has previously disco disease progression	ntinued treatment with pertuzumab and trastuzumab	for reasons other than severe toxicity or	
and	Patient has signs of disease	se progression		
	Disease has not progressed	during previous treatment with pertuzumab and trast	uzumab	